NEWPORT BEACH, Calif., May 20, 2026
CureDuchenne announced a new partnership expansion with Tevard Biosciences to accelerate development of an investigational suppressor tRNA (suptRNA) therapy for Duchenne muscular dystrophy (DMD) caused by nonsense mutations. The collaboration marks CureDuchenne’s second investment in Tevard Biosciences and reinforces growing momentum around next-generation genetic therapies targeting one of the most severe forms of muscular dystrophy.
Suppressor tRNA Platform Targets Nonsense Mutation DMD
Tevard Biosciences is developing a mutation-specific suppressor tRNA platform designed to restore production of full-length dystrophin protein in patients with nonsense mutation DMD. Nonsense mutations introduce premature stop codons in genetic code, preventing the body from producing functional dystrophin protein required for healthy muscle function. Approximately 12% of Duchenne patients carry nonsense mutations, and currently there are no approved therapies specifically designed for this patient population.
The company’s investigational approach works by enabling the cell’s natural translation machinery to “read through” premature stop codons, potentially restoring expression of natural dystrophin protein. According to recently released preclinical findings, Tevard’s latest-generation suppressor tRNA candidates restored an average of 70% wild-type dystrophin protein levels in Duchenne disease models following a single intravenous dose. Researchers also observed functional improvements and durable protein expression, strengthening confidence in the platform’s therapeutic potential.
“CureDuchenne recognized the urgent unmet need facing individuals with nonsense mutations and understood the potential of suppressor tRNA technology to restore full-length, natural dystrophin protein,” said Daniel Fischer, Co-Founder, President and CEO of Tevard Biosciences.
New Data to Be Presented at CureDuchenne FUTURES Conference
Advertisement
For the first time, Tevard Biosciences will publicly present its latest suppressor tRNA data directly to the Duchenne muscular dystrophy community during the CureDuchenne FUTURES National Conference on May 22, 2026. The presentation is expected to provide clinicians, researchers, patient advocates, and families with updated insights into the company’s progress in nonsense mutation DMD research.
In addition, CureDuchenne will host a dedicated webinar with Tevard Biosciences on May 28, 2026, focused on the company’s emerging data and the future potential of suppressor tRNA therapies in Duchenne muscular dystrophy.
CureDuchenne originally invested in Tevard in 2023 after identifying the platform as a promising strategy for addressing major unmet needs in the Duchenne patient community. Since that initial investment, the organization has continued supporting Tevard’s development activities as the company advanced its research and generated additional preclinical evidence.
Growing Momentum in Duchenne Gene and RNA Therapies
The collaboration highlights increasing industry interest in RNA-based and gene-targeted therapies for rare neuromuscular disorders. Unlike conventional approaches focused on symptom management, suppressor tRNA technology aims to directly address the underlying genetic defect responsible for disease progression.
“For families affected by nonsense mutation Duchenne, there remains a critical unmet need for therapies designed specifically for this mutation class,” said Debra Miller, founder and CEO of CureDuchenne. “We continue to be encouraged by the potential of Tevard’s approach to restore full-length dystrophin protein and expand treatment possibilities for individuals who currently have very limited options.”
CureDuchenne stated that its venture philanthropy model has already helped advance multiple Duchenne research programs into human clinical trials. The organization has invested more than $27 million in early-stage Duchenne muscular dystrophy research programs globally.
While Tevard’s suppressor tRNA platform remains in the preclinical stage, the new partnership and encouraging early data position the program as a potentially important future development in the rapidly evolving Duchenne therapeutic landscape.
Source: CureDuchenne press release
